Recent advances on endogenous Na+,K+-ATPase inhibitors: clinical investigation and purification.
Evidence exists which demonstrates the relationship between a Natriuretic Factor or Na+,K+-ATPase inhibitor and volemic expansion, both in man and animal. Patients having extracellular volume expansion have been studied for the effect of their plasma on erythrocytes 3H-ouabain binding. High levels of ouabain-like activity was found in plasma from acromegalic patients and patients with chronic renal failure. High levels were also observed in some hypertensive patients. A partial purification of such a compound was performed from urine of hypertensives. The partially purified compound inhibited to a greater extent the Na+,K+-ATPase semi-purified from dog kidney than that from sheep brain. The present data are consistent with the possible regulation of the activity or the secretion of plasma ouabain-like activity by extracellular volume.
D000172:Acromegaly / Q000097:blood; D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000201:enzymology; D004070:Digitalis / Q000378:metabolism; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000097:blood; D007668:Kidney / Q000201:enzymology; D007676:Kidney Failure, Chronic / Q000097:blood; D007700:Kinetics; D010042:Ouabain / Q000097:blood; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011506:Proteins / Q000302:isolation & purification* / Q000378:metabolism; D013552:Swine; D000097795:ATPase Inhibitory Protein
D010042:Ouabain; D011506:Proteins; D000097795:ATPase Inhibitory Protein